About this trial

This study aims to test the overall hypothesis that the membrane tissue binding capacity of cytokines in the biopsied tissue of patients with Inflammatory Bowel Disease (IBD) is predictive of/strongly correlated to clinical response/outcomes observed.

The key questions under investigation are:

Aim 1: To assess the fluorescent signal intensity at baseline (control antibody with control biopsy and control antibody with IBD biopsy).

Aim 2: To characterize the cellular landscape by surveying surface markers using bar-coded antibodies and performing gene expression profiling on every cell within inflamed tissue of patients with IBD.

Aim 3: Develop algorithm using artificial intelligence to predict responders versus non-responders and to further subclassify IBD patients using phenotype data.

Eligibility criteria

Qualifiers

None

Disqualifiers

Those with previous allergy to fluorescein

Pregnant and breastfeeding patients

Trial design

Treatments tested in this trial

  • Confocal Laser Endomicroscopy

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

2
University of Texas at Arlington76010, ArlingtonTexas, United States
Cook Children's Health Care System76104, Fort WorthTexas, United States

Sponsors and collaborators

Cook Children's Health Care System

Lead sponsor